Hyderabad: In order to ramp up the Covid-19 vaccine production, Hyderabad-based vaccine makers Indian Immunologicals Ltd (IIL) and Bharat Biotech International Limited (BBIL) joined hands in April 2021 to produce drug substance for Covaxin, and IIL has enhanced capacities since then. Dr K Anand Kumar, MD, IIL handed over the first batch of Covaxin drug substance to Dr Krishna Ella, CMD, Bharat Biotech on Friday. IIL in a short period of time has performed several activities including signing of four agreements with BBIL, repurposing its manufacturing facility in Hyderabad, procurement of key raw materials and consumables, procurement of key equipment for the process, technology transfer, trials at R&D scale and training.
Speaking on this occasion, Dr K Anand Kumar, MD, IIL said, “This is Team India at work.Our capable and competent team worked tirelessly round the clock to ensure that the committed timelines and product quality are met. This would have not been possible without the constant support provided by Niti Aayog, BIRAC, DBT, Mission Covid Suraksha Team, Central and State drug control authorities.”
Dr Renu Swarup, secretary, DBT and chairperson, BIRAC said, “The government has worked relentlessly to provide all possible support for ramping up Covaxin production in the country and speed up Covaxin inoculation drive. IIL is also working on another Covid -19 vaccine and the animal trials are underway currently and is expected to come out by next year for human vaccination,” Dr Anand Kumar added. The Indian Immunologicals Limited (IIL), Hyderabad has been sanctioned a grant of Rs 60 crore towards enhancing production capabilities.
Corona vaccine awareness chariot to motivate Muslims to get vaccinated
Is it Right Time to Buy? Low Gold Price, May Touch Rs 50,000 Soon.